نتائج البحث - "Desmond Chee"

المصدر: Journal of Crohn's and Colitis, 16, 3, pp. 389-397
Journal of Crohn's & Colitis
Journal of Crohn's and Colitis, 16, 389-397
Chanchlani, N, Lin, S, Chee, D, Hamilton, B, Nice, R, Arkir, Z, Bewshea, C, Cipriano, B, Derikx, L A A P, Dunlop, A, Greathead, L, Griffiths, R L, Ibraheim, H, Kelleher, P, Kok, K B, Lees, C W, MacDonald, J, Sebastian, S, Smith, P J, McDonald, T J, Irving, P M, Powell, N, Kennedy, N A, Goodhand, J R & Ahmad, T 2022, ' Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses : Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients ', Journal of Crohn's & colitis, vol. 16, no. 3, pp. 389-397 . https://doi.org/10.1093/ecco-jcc/jjab153Test

مصطلحات موضوعية: Male, TNF, Gastroenterology, Serology, Seroepidemiologic Studies, adalimumab, skin and connective tissue diseases, immunosuppression, biology, medicine.diagnostic_test, General Medicine, Eccojc/1020, Original Article, Drug Monitoring, Antibody, Life Sciences & Biomedicine, biologic, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], medicine.drug, vedolizumab, Adult, medicine.medical_specialty, Combination therapy, MATURATION, Vedolizumab, DEFICIENT, inflammatory bowel disease, Internal medicine, Adalimumab, medicine, Humans, Seroprevalence, AcademicSubjects/MED00260, Biological Products, Science & Technology, Gastroenterology & Hepatology, SARS-CoV-2, business.industry, COVID-19, 1103 Clinical Sciences, vaccination, Inflammatory Bowel Diseases, Infliximab, ALPHA, Therapeutic drug monitoring, CLARITY, Antibody Formation, biology.protein, Tumor Necrosis Factor Inhibitors, infliximab, business, INFLAMMATORY-BOWEL-DISEASE

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c08447d7329ab51228946a10f8ee899Test

8

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients

مصطلحات موضوعية: Drug, biology, business.industry, media_common.quotation_subject, medicine.disease, Inflammatory bowel disease, Infliximab, Vedolizumab, Vaccination, Immunity, Immunology, biology.protein, medicine, Antibody, Seroconversion, skin and connective tissue diseases, business, media_common, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::53340a469770e6f6c6b039706dfb33a6Test
https://doi.org/10.1101/2021.11.10.21266168Test

9

Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients

مصطلحات موضوعية: Coronavirus disease 2019 (COVID-19), biology, business.industry, Immunology, biology.protein, Medicine, Antibody, business, Infliximab, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::102d27fb2d4bd090e65a82c5ced42b46Test
https://doi.org/10.21203/rs.3.rs-755879/v1Test

10

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

المساهمون: Kennedy, Nicholas A [0000-0003-4368-1961], Lin, Simeng [0000-0002-4201-4879], Goodhand, James R [0000-0003-3112-376X], Chanchlani, Neil [0000-0003-0207-6706], Hamilton, Benjamin [0000-0002-0349-278X], Bewshea, Claire [0000-0002-0965-9587], Chee, Desmond [0000-0003-3473-9447], Cummings, Jr Fraser [0000-0002-9659-3247], Fraser, Aileen [0000-0001-6462-5091], Irving, Peter M [0000-0003-0972-8148], Kok, Klaartje B [0000-0002-5942-9149], Lamb, Christopher Andrew [0000-0002-7271-4956], Macdonald, Jonathan [0000-0003-0249-107X], Mehta, Shameer [0000-0002-7002-293X], Pollok, Richard Cg [0000-0001-6452-6763], Raine, Tim [0000-0002-5855-9873], Smith, Philip J [0000-0003-1568-3978], Verma, Ajay Mark [0000-0002-6432-3357], McDonald, Timothy J [0000-0003-3559-6660], Sebastian, Shaji [0000-0002-3670-6545], Lees, Charlie W [0000-0002-0732-8215], Powell, Nick [0000-0003-3231-6950], Ahmad, Tariq [0000-0002-6058-5528], Apollo - University of Cambridge Repository

المصدر: 2021, ' Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD ', Gut . https://doi.org/10.1136/gutjnl-2021-324789Test
Gut

مصطلحات موضوعية: 0301 basic medicine, Male, TNF, inflammatory diseases, Antibodies, Viral, Gastroenterology, 0302 clinical medicine, vaccine, skin and connective tissue diseases, education.field_of_study, biology, Immunogenicity, Middle Aged, Vaccination, 030211 gastroenterology & hepatology, Female, Antibody, medicine.drug, vedolizumab, Adult, medicine.medical_specialty, COVID-19 Vaccines, Population, autoimmune disease, Antibodies, Monoclonal, Humanized, Vedolizumab, 03 medical and health sciences, Gastrointestinal Agents, Immunity, inflammatory bowel disease, Internal medicine, ChAdOx1 nCoV-19, medicine, Humans, Serologic Tests, Seroconversion, education, BNT162 Vaccine, Biological Products, business.industry, SARS-CoV-2, COVID-19, Inflammatory Bowel Diseases, Infliximab, 030104 developmental biology, CLARITY, Antibody Formation, biology.protein, BNT162b2, business

وصف الملف: application/pdf; text/xml; application/vnd.openxmlformats-officedocument.wordprocessingml.document

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fffd47718a4ac7f2145f7f6e36c5f51fTest
https://www.pure.ed.ac.uk/ws/files/210537673/gutjnl_2021_324789.full.pdfTest

تنقيح النتائج